C
Christophe Caux
Researcher at French Institute of Health and Medical Research
Publications - 254
Citations - 32907
Christophe Caux is an academic researcher from French Institute of Health and Medical Research. The author has contributed to research in topics: Immune system & Dendritic cell. The author has an hindex of 74, co-authored 232 publications receiving 30760 citations. Previous affiliations of Christophe Caux include Centre national de la recherche scientifique & International Facility Management Association.
Papers
More filters
Journal ArticleDOI
Que retenir dans la prise en charge des cancers en 2022 ?
Jacques-Olivier Bay,Carole Bouleuc,Christophe Caux,Frédéric Delom,Nelly Firmin,Virginie Gandemer,Gilles L'Allemain,Nicolas Magné,Daniel Orbach,Jacques Robert,Manuel Rodrigues,Renaud Sabatier,Antoine Thiery-Vuillemin,Marie Wislez +13 more
TL;DR: The Cancer Bulletin continues its tradition of publishing a summary of the highlights of the previous year's Cancer Bulletin this article , focusing on published data and placing them in the more general context of the management of each type of cancer to deduce the practical consequences for patients.
Journal ArticleDOI
Heterogeneity and Functions of Tumor-Infiltrating Antibody Secreting Cells: Lessons from Breast, Ovarian, and Other Solid Cancers
Yasmine Lounici,Olivia Le Saux,Gabriel Chemin,Pauline Wajda,Sarah Barrin,Justine Berthet,Christophe Caux,Bertrand Dubois +7 more
TL;DR: The current knowledge on the heterogeneity of tumor-infiltrating ASCs is summarized, their possible local or systemic origin in relation to their immunoglobulin repertoire is discussed, and the different mechanisms by which antibody subclasses and isoforms differentially impact tumor cells and anti-tumor immunity are reviewed.
Patent
Use of the combinatory diversity of the catalogue of T lymphocytes as a cancer prognostic marker
Manuel Manuarii,Christophe Caux,Jean-François Mouret,Christine Ménétrier-Caux,Nicolas Pasqual,Thomas Bachelot,Jean-Yves Blay +6 more
TL;DR: In this article, a method for ex vivo or in vitro prognosis of an individual suffering from a solid cancer, comprises: (i) measuring the level of diversity of T cell repertoire of the individual by nucleic acid from a biological sample containing white cells of theindividual; and (ii) comparing with a predetermined threshold, the individual having a high risk of early death.
Journal ArticleDOI
[Tertiary lymphoid structures in cancer: From biology to therapeutic guides].
TL;DR: Tertiary lymphoid structures (TLS) are inducible ectopic lymphoid aggregates, which form in response to various inflammatory situations, including cancer as discussed by the authors , which are notably composed of B lymphocytes, T lymphocyte, mature dendritic cells and other key players such as high endothelial venules.
Journal ArticleDOI
Pembrolizumab in Lymphopenic Metastatic Breast Cancer Patients Treated with Metronomic Cyclophosphamide: A Clinical and Translational Prospective Study
Benoîte Méry,Christine Ménétrier-Caux,L. Montané,Pierre-Etienne Heudel,Isabelle Ray-Coquard,Thomas Bachelot,Olfa Derbel,Paule Augereau,Isabelle Treilleux,Justine Berthet,Christine Bardin-dit-Courageot,Valéry Attignon,Anthony Ferrari,Gwenaelle Garin,David Pérol,Christophe Caux,Bertrand Dubois,Olivier Tredan +17 more
TL;DR: In this article , the authors evaluated the safety and clinical activity of pembrolizumab (intravenous (IV), 200mg, every 3 weeks) combined with metronomic cyclophosphamide (50mg/day, per os) in a prospective cohort of lymphopenic patients with HER-2 negative MBC.